Trial Profile
Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 Apr 2024
Price :
$35
*
At a glance
- Drugs Naltrexone/bupropion (Primary)
- Indications Binge-eating disorder; Obesity
- Focus Therapeutic Use
- 26 Sep 2023 Results published in the Obesity (Silver Spring, Md.)
- 30 Jun 2023 Status changed from active, no longer recruiting to completed.
- 12 Jan 2023 Planned End Date changed from 1 Jun 2025 to 1 May 2023.